Abstract Library

#131 Efficacy and safety results from a Phase II study of pasireotide (SOM230) in the treatment of patients with metastatic NETs refractory or resistant to octreotide LAR

Introduction: Pasireotide, a multi-receptor targeted somatostatin analogue, has 30-, 5- and 39-fold greater affinity for sst1,3 and sst5 receptors, respectively, and a slightly lower affinity for sst2, than octreotide. Because of this multi-receptor binding profile, pasireotide may be effective in controlling symptoms of carcinoid syndrome in patients with gastroenteropancreatic neuroendocrine tumors (NETs) who are no longer responsive to currently available somatostatin analogues.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Kvols L

Authors: Kvols L, Wiedenmann B, Öberg K, Mohideen P, O’Dorisio T,

Keywords: Pasireotide, SOM230, octreotide, carcinoid, diarrhea, flushing, efficacy ,